Сравнение

Ganirelix vs. Lanreotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

123246-29-7

108736-35-2

Молекулярная масса

1570.3 g/mol

1096.34 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Ganirelix

Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Ganirelix	Lanreotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Ganirelix and Lanreotid?: Ganirelix is classified as "Исследования (прочее)", while Lanreotid is classified as "Исследования (прочее)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Ganirelix or Lanreotid?: The highest available evidence level is "РКИ на людях" for Ganirelix and "РКИ на людях" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Ganirelix and Lanreotid in Germany and the United States?: Германия: Ganirelix — Рецептурный, Lanreotid — Рецептурный. США: Ganirelix — Рецептурный, Lanreotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Ganirelix

Lanreotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Ganirelix and Lanreotid?

Ganirelix is classified as "Исследования (прочее)", while Lanreotid is classified as "Исследования (прочее)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Ganirelix or Lanreotid?

The highest available evidence level is "РКИ на людях" for Ganirelix and "РКИ на людях" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Ganirelix and Lanreotid in Germany and the United States?

Германия: Ganirelix — Рецептурный, Lanreotid — Рецептурный. США: Ganirelix — Рецептурный, Lanreotid — Рецептурный. These are factual summaries with source and review date on the individual pages.